TNX-2110 + TNX-2120 + TNX-2130 + CANDIN + Diluent

Phase 1Terminated

0 views this week 0 watching💤 Quiet

Interest: 11/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2

Conditions

Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2

Trial Timeline

Jan 7, 2022 → Sep 17, 2022

NCT ID

NCT05216510

About TNX-2110 + TNX-2120 + TNX-2130 + CANDIN + Diluent

TNX-2110 + TNX-2120 + TNX-2130 + CANDIN + Diluent is a phase 1 stage product being developed by Tonix Pharmaceuticals for Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2. The current trial status is terminated. This product is registered under clinical trial identifier NCT05216510. Target conditions include Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05216510	Phase 1	Terminated	Jan 7, 2022	Sep 17, 2022	Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2

Competing Products

2 competing products in Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2

See all competitors

Product	Company	Stage	Hype Score
Tapentadol IR + Oxycodone IR	Johnson & Johnson	Pre-clinical	26
ECMPS-IEM	Novartis	Phase 2	35